| 1 |
34706060 | Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy. | 2022 Feb 15 |
1 |
| 2 |
32052681 | Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage. | 2021 |
1 |
| 3 |
33307872 | New insights into the clinical management of advanced gastrointestinal stromal tumors. | 2021 Mar |
1 |
| 4 |
34702313 | The role of PDGFRA as a therapeutic target in young colorectal cancer patients. | 2021 Oct 26 |
2 |
| 5 |
32457362 | Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways. | 2020 Aug |
1 |
| 6 |
32497121 | dBMHCC: A comprehensive hepatocellular carcinoma (HCC) biomarker database provides a reliable prediction system for novel HCC phosphorylated biomarkers. | 2020 |
2 |
| 7 |
26599335 | Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models. | 2015 |
1 |
| 8 |
28031906 | Clinical activity of regorafenib in PDGFRA-mutated gastrointestinal stromal tumor. | 2015 Nov |
3 |
| 9 |
24384849 | Gastrointestinal stromal tumors: what do we know now? | 2014 Jan |
1 |
| 10 |
24405315 | Regorafenib for treatment of advanced gastrointestinal stromal tumors. | 2014 Mar |
2 |